Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a pathological subtype of lung neuroendocrine cancer, which accounts for 2.4%-3.1% in surgical specimens of lung cancer. It is characterized by high invasiveness and poor prognosis, and highly correlated with smoking. There are few relevant studies due to the low incidence and small sample size. Therefore, it is relatively difficult to diagnosis and treatment in clinical practice. In this review, we described molecular subtype, diagnostic and prognostic-related markers about large cell neuroendocrine carcinoma of lung based on the recent progress in genomic sequencing and molecular markers, to find the direction for the next research. .
【中文题目：肺大细胞神经内分泌癌分子标志物的 研究进展】 【中文摘要：肺大细胞神经内分泌癌（pulmonary large cell neuroendocrine carcinoma, LCNEC）为肺神经内分泌癌的一种病理亚型，其发病率占肺癌手术标本的2.4%-3.1%，具有侵袭性高、预后差的特点，与吸烟高度相关。因发病率低、样本量少的原因导致相关研究较少，因此在临床上对肺LCNEC的诊断及治疗相对困难。本文结合近年肺大细胞神经内分泌癌相关基因测序及分子标志物的研究进展，对其分子分型、诊断及预后相关生物标志物进行阐述，为下一步研究方案寻找方向。 】 【中文关键词：肺大细胞神经内分泌癌；分子分型；诊断相关标志物；预后相关标志物】.
Keywords: Diagnostic-related marker; Molecular subtype; Prognostic-related marker; Pulmonary large cell neuroendocrine carcinoma.